Debate Series - Estro-events.org
Debate Series - Estro-events.org
Debate Series - Estro-events.org
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
posTErs<br />
Posters<br />
Page 424 PROgRammE & ExhibiTiOn guidE • WCB 2012<br />
abS. numbER<br />
> Prediction of erectile dysfunction following prostate brachytherapy:<br />
a dose volume analysis of penile structures<br />
C. Beaufort (Australia), B. Hindson, E. Paul PO-178<br />
> Three year results of HDR-brachytherapy for prostate cancer treated<br />
with new regimen of 45.5 gy in seven fractions<br />
K. Konishi (Japan), Y. Yoshioka, Y. Takahashi, T. Ogata, F. Isohashi,<br />
M. Koizumi, K. Ogawa PO-179<br />
> Clinical outcome of 195 low or intermediate risk prostate cancer<br />
treated by permanent implant brachytherapy<br />
C. Verry (France), C. Thullier, J.A. Long, J.Y. Giraud, J.L. Descotes,<br />
M. Bolla PO-180<br />
> Urethra constraint on 160 Gy exclusive prostate permanent brachytherapy<br />
J. Richart Sancho (Spain), S. Rodriguez, M. Santos, M. Depiaggio,<br />
J. Perez-Calatayud, F. Ballester PO-181<br />
> Intra-operative real-time planned permanent-seed prostate BT:<br />
impact of training program and learning curve<br />
T. Zilli (Canada), M. Alizadeh, D. Taussky PO-182<br />
> Prostate cancer boost using HDR brachytherapy: learning curve<br />
analysis after 103 consecutive patients<br />
H. Hijazi (France), M.E. Chand-Fouche, J. Gal, M. Gauthier, C. Dejean,<br />
J.M. Hannoun-Levi PO-183<br />
> Correlation of a bioeffect model with tumour control in localised<br />
prostate cancer treated with I-125 implant<br />
A. Haworth (Australia), A. Haworth, S. Williams, S. Williams,<br />
H. Reynolds, D. Joseph, M. Ebert, M. Ebert PO-184<br />
> Two HDR brachytherapy schedules as monotherapy in prostate cancer:<br />
analysis of toxicity in 178 patients<br />
A. Colombo (Italy), C. Frigerio, G. Sangalli, R. D’Amico, S. Sacco,<br />
F. Declich, F. Placa PO-185<br />
Posters<br />
abS. numbER<br />
> Low dose rate brachytherapy with permanent seeds of I-125<br />
in prostate cancer. Clinical and dosimetric analysis<br />
M.A. Gentil Jiménez (Spain), R. Guerrero Tejada, M.I. Tovar Martín,<br />
M. Martínez Carrillo, J.A. Bullejos, A. Suárez Charneco,<br />
M.P. Vargas Arrabal, I. Linares Galiana, J. Expósito Hernández,<br />
R. Del Moral Ávila PO-186<br />
> Brachytherapy for prostate cancer: experience in LDR and HDR<br />
irradiation<br />
I. Albitskiy (Russian Federation), S. Ivanov, A. Pavlov, G. Panshin,<br />
P. Datsenko, K. Milenin, A. Vinikovetskaya, A. Teliyants, S. Golub PO-187<br />
> Prostate HDR brachytherapy catheter displacement between<br />
planning and treatment delivery at Sydney Cancer Centre<br />
M. Whitaker (Australia), G. Hruby, A. Lovett, G. Perez, S. Kaldas,<br />
N. Patanjali PO-188<br />
> A novel image-fusion technique between CT and T2-weighted MR<br />
images for postimplant dosimetry after brachytherapy<br />
H. Kunogi (Japan), H. Hojo, M. Nakashiro, Y. Wakumoto, K. Sasai PO-189<br />
> The efficacy of a1 –blockers for acute urinary symptoms after<br />
iodine-125 prostate brachytherapy<br />
K. Tadahiko, A. Kouji (Japan), T. Nozomu, Y. Masayoshi, N. Atsushi PO-190<br />
> Predictors of distant metastasis after external beam radiation<br />
and HDR brachytherapy boost for prostate cancer<br />
W.C. Lorentz (USA), D.J. Demanes, J. Wang, M. Kamrava PO-191<br />
> Prostate cancer boost using HDR brachytherapy: early toxicity<br />
analysis of 3 different fractionation schemes<br />
M.E. Chand-Fouché (France), H. Hijazi, J. Gal, J. Feuillade,<br />
C. Dejean, J.M. Hannoun-Levi PO-192<br />
> High dose rate brachytherapy as monotherapy for early-stage<br />
prostate cancer: toxicity and early results<br />
S. Aluwini (The Netherlands), P. van Rooij, J. Praag, P. Jansen,<br />
C. Jauns, W. Kirkels, I. Kolkman-Deurloo PO-193<br />
WCB 2012 • PROgRammE & ExhibiTiOn guidE Page 425<br />
posTErs<br />
WCB
Change language